Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Randomized Phase II Trial of Combination Idiotype Vaccine and Anti-CD3/Anti-CD28 Costimulated Autologous T Cells in Patients with Multiple Myeloma Post-Autotransplantation

Blood (2016) 128 (22): 4548.

https://doi.org/10.1182/blood.V128.22.4548.4548

Published: 2016

Journal Articles

Randomized, Double-Blind, Placebo-Controlled, Dose and Schedule-Finding Study of AMG 531 In Chemotherapy-Induced Thrombocytopenia (CIT): Results of a Phase I/II Study.

Saroj Vadhan-Raj, MD, Fredrick Hagemeister, Luis E. Fayad, MD, Xiao Zhou, MD, PHD, Shana Sherril ORoark, APN, Kandice Ames, RN, Maria Alma Rodriguez, MD, Michelle A. Fanale, MD, Barbara Pro, MD, Marcella M. Johnson, MS, Peter McLaughlin, MD, Carlos E. Bueso-Ramos, Anas Younes, MD, Larry Kwak, MD, PHD, Jorge Enrique Romaguera

Blood (2010) 116 (21): 1544.

https://doi.org/10.1182/blood.V116.21.1544.1544

Published: 2010

Journal Articles

Role of Microenvironment In Mantle Cell Lymphoma: IL-6 as An Important Survival Factor for Tumor Cells

Liang Zhang, MD, PhD, Jing Yang, PhD, Jianfei Qian, PhD, Sattva Neelapu, MD, Larry Kwak, MD, PhD, Michael Wang, MD, Qing Yi, MD, PhD

Blood (2010) 116 (21): 3929.

https://doi.org/10.1182/blood.V116.21.3929.3929

Published: 2010

Journal Articles

Bone Loss in Lymphoma Patients Receiving Frontline Therapy: Urine NTx and Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response.

Jason R. Westin, MD, Michael A. Thompson, MD, PhD, Vince D. Cataldo, MD, Bela B. Toth, D.D.S., Perpetua Sanjorjo, Scott Bourgeois, M.D., Camilo Jimenez, M.D., William A. Murphy, M.D., Michelle Fanale, M.D., Luis Fayad, M.D., Nathan Fowler, M.D., Larry Kwak, MD, PHD, Peter McLaughlin, MD, Sattva Neelapu, MD, Barbara Pro, M.D., Alma Rodriguez, M.D., Jatin Shah, MD, Fredrick B. Hagemeister, MD

Blood (2009) 114 (22): 3922.

https://doi.org/10.1182/blood.V114.22.3922.3922

Published: 2009

Journal Articles

Phase I Multi-Dose Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion Every 3 Weeks to Patients with Relapsed/ Refractory B-Cell Non-Hodgkin's Lymphoma (NHL).

Anas Younes, MD, Leo Gordon, MD, Stella Kim, MD, Jorge Romaguera, MD, Amanda R Copeland, MS, Silvana de Castro Farial, MD, Larry Kwak, MD, PHD, Luis Fayad, MD, Frederick Hagemeister, MD, Michelle Fanale, M.D., John Lambert, PhD, Teresa Bagulho, MD, Rodica Morariu-Zamfir, MD

Blood (2009) 114 (22): 585.

https://doi.org/10.1182/blood.V114.22.585.585

Published: 2009

Journal Articles

Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing Vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome.

Saroj Vadhan-Raj, MD, Luis Fayad, MD, Michelle Fanale, M.D., Barbara Pro, Alma Rodriguez, Frederick Hagemeister, Kandice Ames, RN, Carlos E. Bueso-Ramos, MD, Xiao Zhou, MD, PHD, Peter McLaughlin, Nathan Fowler, Jatin Shah, MD, Felipe Samaniego, MD, Anas Younes, MD, Larry Kwak, MD, PHD, Jorge Romaguera, MD

Blood (2009) 114 (22): 105.

https://doi.org/10.1182/blood.V114.22.105.105

Published: 2009

Journal Articles

A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma.

Luhua Wang, MD, Luis Fayad, MD, Fredrick B. Hagemeister, MD, Sattva Neelapu, MD, Felipe Samaniego, MD, Peter McLaughlin, MD, Barry Samuels, MD, Qing Yi, MD, PhD, Barbara Pro, MD, Michelle Fanale, M.D., Jatin Shah, MD, Anas Younes, MD, Neda Bell, Robert Knight, MD, Jerome B. Zeldis, MD, PhD, Fernando Cabanillas, MD, Larry Kwak, MD, PHD, Jorge Romaguera, MD

Blood (2009) 114 (22): 2719.

https://doi.org/10.1182/blood.V114.22.2719.2719

Published: 2009

Journal Articles

Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma

Jorge Romaguera, MD, Luis Fayad, Peter McLaughlin, MD, Barbara Pro, MD, Maria Alma Rodriguez, MD, Michael Wang, MD, Pamela Weaver, RN, Kimberly Hartig, Larry Kwak, MD, PhD, Tatyana Feldman, MD, Judy Smith, RN, Peggy Ford, RN, Stuart Goldberg, MD, Andrew Pecora, MD, Andre Goy, MD

Blood (2008) 112 (11): 3051.

https://doi.org/10.1182/blood.V112.11.3051.3051

Published: 2008

Journal Articles

Preliminary Results of a Phase II Study of HCVIDDoxil Alternated with Methotrexate-Cytarabine in Patients with Newly Diagnosed T-Cell Lymphoma.

Barbara Pro, MD, Luis Fayad, MD, Jorge Romaguera, MD, Michelle Fanale, MD, Anas Younes, MD, Fredrick B. Hagemeister, MD, Felipe Samaniego, MD, Peter McLaughlin, MD, M.A. Rodriguez, MD, Larry Kwak, MD, PhD, Nam H. Dang, MD

Blood (2007) 110 (11): 3456.

https://doi.org/10.1182/blood.V110.11.3456.3456

Published: 2007

Journal Articles

R-HCVAD/R-MTX-ARAC Is an Effective Regimen for Untreated Diffuse Large B-Cell Lymphoma (DLBCL) with Aggressive Features in Patients Younger Than 60 Years

Luis Fayad, MD, Barbara Pro, MD, Fredrick Hagemeister, MD, Fernando Cabanillas, MD, Felipe Samaniego, MD, Peter McLaughlin, MD, Michael Wang, MD, Sattva Neelapu, MD, Larry Kwak, MD, PhD, Jorge Romaguera, MD, Maria A. Rodriguez, MD

Blood (2007) 110 (11): 1285.

https://doi.org/10.1182/blood.V110.11.1285.1285

Published: 2007

Journal Articles

The Addition of Rituximab to CHOP Chemotherapy Improves Response Rate, Failure-Free Survival and Overall Survival for Follicular Grade 3 Lymphoma Compared to CHOP Alone

Michael J. Overman, MD, Lei Feng, MS, Barbara Pro, MD, Peter McLaughlin, MD, Mark Hess, BBA, Felipe Samaniego, MD, Anas Younes, MD, Jorge E. Romaguera, MD, Frederick B. Hagemeister, MD, Larry Kwak, MD, PhD, Fernando Cabanillas, MD, Maria A. Rodriguez, MD, Luis E. Fayad, MD

Blood (2007) 110 (11): 1289.

https://doi.org/10.1182/blood.V110.11.1289.1289

Published: 2007

Journal Articles

Lenalidomide (Len) in Combination with Rituximab (R) Demonstrated Early Evidence of Efficacy in a Phase I/II Study in Relapsed/Refractory Mantle Cell Lymphoma (MCL).

Michael Wang, MD, Luis Fayad, MD, Frederick Hagemeister, MD, Sattva Neelapu, MD, Barry Samuels, MD, Felipe Samanigo, MD, Barbara Pro, MD, Qing Yi, MD, PhD, Neda Bell, Catriona Byrne, Pam Weaver, Kim Hartig, Robert Knight, MD, Jerry Zeldis, MD, Larry Kwak, MD, PhD, Jorge Romaguera, MD

Blood (2007) 110 (11): 2562.

https://doi.org/10.1182/blood.V110.11.2562.2562

Published: 2007

Journal Articles

Longer Follow-Up Confirms a Low Relapse Rate after Non-Myeloablative Allogeneic Transplantation (NMT) for Non-Hodgkin’s Lymphoma (NHL), Including Patients with PET or Gallium-Avid Disease.

Issa F. Khouri, MD, Rima M. Saliba, PhD, Ming-Sheng Lee, MD, Grace-Julia Okoroji, Luis Fayad, MD, Farzaneh Maadani, Chitra Hosing, MD, Barry Samuels, MD, Sergio Giralt, MD, Marcos de Lima, MD, Barbara Pro, MD, Anas Younes, MD, Peter McLaughlin, MD, Larry Kwak, MD, PhD, Richard E. Champlin, MD

Blood (2005) 106 (11): 44.

https://doi.org/10.1182/blood.V106.11.44.44

Published: 2005

Journal Articles

High (95%) Response Rates in Relapsed/Refractory Mantle Cell Lymphoma after R-HCVAD Alternating with R-Methotrexate/Cytarabine (R-M-A).

Jorge Enrique Romaguera, MD, Luis E. Fayad, MD, Michael Wang, MD, Fernando Cabanillas, MD, Fredrick Hagemeister, MD, Peter McLaughlin, MD, Alma Rodriguez, MD, Anas Younes, MD, Sattva Neelapu, MD, Andre H. Goy, MD, Virginia Beasley, Larry Kwak, MD, PhD

Blood (2005) 106 (11): 2446.

https://doi.org/10.1182/blood.V106.11.2446.2446

Published: 2005

Journal Articles

Interim Analysis of a Phase II Study of the Combination of Denileukin Diftitox (Ontak) and Rituximab for Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma.

Nam H. Dang, MD, PhD, Peter McLaughlin, MD, Luis Fayad, MD, Jorge Romaguera, MD, Fredrick Hagemeister, MD, Anas Younes, MD, Sattva Neelapu, MD, Felipe Samaniego, MD, Dan Jones, MD, PhD, Pamela L. Walker, RN, Maria A. Rodriguez, MD, Larry Kwak, MD, PhD, Barbara Pro, MD

Blood (2005) 106 (11): 3349.

https://doi.org/10.1182/blood.V106.11.3349.3349

Published: 2005

Journal Articles

Phase II Study of Denileukin Diftitox (Ontak) for Relapsed/Refractory T-Cell Non-Hodgkin’s Lymphoma.

Nam H. Dang, MD, PhD, Barbara Pro, MD, Fredrick Hagemeister, MD, Felipe Samaniego, MD, Dan Jones, MD, PhD, Maria Rodriguez, MD, Andre Goy, MD, Jorge Romaguera, MD, Pamela L. Walker, RN, Anas Younes, MD, Sattva Neelapu, MD, Larry Kwak, MD, PhD, Luis Fayad, MD

Blood (2005) 106 (11): 3350.

https://doi.org/10.1182/blood.V106.11.3350.3350

Published: 2005

Journal Articles

Six Weekly Doses of Rituximab Plus ABVD for Newly Diagnosed Patients with Advanced Stage Classical Hodgkin Lymphoma: Depletion of Reactive B-Cells from the Microenvironment by Rituximab.

Anas Younes, MD, Peter McLaughlin, MD, Luis E. Fayad, MD, Andre Goy, MD, Jorge E. Romaguera, MD, Barbara Pro, MD, Maria A. Rodriguez, MD, Felipe Samaniego, MD, Larry Kwak, MD, PhD, Sattva Neelapu, M.D., Jeffrey Medeiros, MD

Blood (2005) 106 (11): 1499.

https://doi.org/10.1182/blood.V106.11.1499.1499

Published: 2005

Journal Articles

Interim Analysis of a Phase II Study of Denileukin Diftitox (Ontak) for Relapsed/Refractory T-Cell Non-Hodgkin’s Lymphoma.

Nam H. Dang, MD, PhD, Barbara Pro, MD, Fredrick B. Hagemeister, MD, Dan Jones, MD, PhD, Barry Samuels, MD, Maria A. Rodriguez, MD, Andre Goy, MD, Jorge E. Romaguera, MD, Pamela L. Walker, RN, Larry Kwak, MD, PhD, Luis Fayad, MD

Blood (2004) 104 (11): 2641.

https://doi.org/10.1182/blood.V104.11.2641.2641

Published: 2004

NARROW

Randomized Phase II Trial of Combination Idiotype Vaccine and Anti-CD3/Anti-CD28 Costimulated Autologous T Cells in Patients with Multiple Myeloma Post-Autotransplantation

Randomized, Double-Blind, Placebo-Controlled, Dose and Schedule-Finding Study of AMG 531 In Chemotherapy-Induced Thrombocytopenia (CIT): Results of a Phase I/II Study.

Role of Microenvironment In Mantle Cell Lymphoma: IL-6 as An Important Survival Factor for Tumor Cells

Bone Loss in Lymphoma Patients Receiving Frontline Therapy: Urine NTx and Bone Specific Alkaline Phosphatase Provide Early Evidence of Zoledronic Acid Response.

Phase I Multi-Dose Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion Every 3 Weeks to Patients with Relapsed/ Refractory B-Cell Non-Hodgkin's Lymphoma (NHL).

Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing Vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome.

A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma.

Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma

Preliminary Results of a Phase II Study of HCVIDDoxil Alternated with Methotrexate-Cytarabine in Patients with Newly Diagnosed T-Cell Lymphoma.

R-HCVAD/R-MTX-ARAC Is an Effective Regimen for Untreated Diffuse Large B-Cell Lymphoma (DLBCL) with Aggressive Features in Patients Younger Than 60 Years

The Addition of Rituximab to CHOP Chemotherapy Improves Response Rate, Failure-Free Survival and Overall Survival for Follicular Grade 3 Lymphoma Compared to CHOP Alone

Lenalidomide (Len) in Combination with Rituximab (R) Demonstrated Early Evidence of Efficacy in a Phase I/II Study in Relapsed/Refractory Mantle Cell Lymphoma (MCL).

Longer Follow-Up Confirms a Low Relapse Rate after Non-Myeloablative Allogeneic Transplantation (NMT) for Non-Hodgkin’s Lymphoma (NHL), Including Patients with PET or Gallium-Avid Disease.

High (95%) Response Rates in Relapsed/Refractory Mantle Cell Lymphoma after R-HCVAD Alternating with R-Methotrexate/Cytarabine (R-M-A).

Interim Analysis of a Phase II Study of the Combination of Denileukin Diftitox (Ontak) and Rituximab for Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma.

Phase II Study of Denileukin Diftitox (Ontak) for Relapsed/Refractory T-Cell Non-Hodgkin’s Lymphoma.

Six Weekly Doses of Rituximab Plus ABVD for Newly Diagnosed Patients with Advanced Stage Classical Hodgkin Lymphoma: Depletion of Reactive B-Cells from the Microenvironment by Rituximab.

Interim Analysis of a Phase II Study of Denileukin Diftitox (Ontak) for Relapsed/Refractory T-Cell Non-Hodgkin’s Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only